So nothing to do with good clinical data and better outcomes ? Sirtex is approved in primary and secondary liver where hepatic artery access gives the interventional oncologist direct access to the tumour blood flow, all liver tumours feed off an extended hepatic artery vasculature and ensures no extra hepatic radiation. Two procedures, one to map the tumour and support dose calculation then the second to inject the dose. In panc its totally different. Sirtex iand Therasphere and diferent not better. What makes them better is data and outcomes not procedural factors. Med Onc dont care about how its given, they care about outcomes.Thats why Sirtex and Therasphere are currently seem by the Oncs as , at best second line treatments, if not salvage outside of primary liver cancer. OSL needs to change that perception in its target patinets to ensure success.
OSL Price at posting:
5.1¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)